$VIR

$11.04 +$0.47 (4.45%) Close

$VIR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 169.2M shares outstanding

Who owns VIR?

By type of holder

Institutions 86.4% Insiders 11.8% Everyone else 1.8%

Concentration Top 10 holders own 81.4%

BlackRock, Inc. 12.2% · Robert Nelsen 8.0%

Institutional ownership

86.4%

+3.6 pts vs last qtr

Institutional holders

235

-17 vs last qtr

Net shares bought

+6.1M

by institutions in Q2 2026

New / sold out

32 / 49

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Point72 Asset Management, L.P. +3.7M
State Street Corp +2.8M

Biggest sellers in Q2 2026

Jacobs Levy Equity Management, Inc −1.3M
Citadel Advisors LLC −1.1M

Who is planning to sell?

Notices of proposed sale, last 12 months

$25.4M

33 notices from 9 people

Shares covered

3.5M

2.04% of the company

Arranged in advance

72%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

SVF Endurance (Cayman) Limited Stockholder $20.4M
Vicki Lee Sato Director 10b5-1 $1.35M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2020–FY2025

+16.2%

+3.06% a year

Each share's claim on the business

−14.0%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $452M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years56% 3–5 years8% 1–3 years14% Under 1 year22%

Quarterly turnover

13.7%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting VIR on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
B BlackRock, Inc.	20.7M	12.22%	+2.7M (+14.9%)	≤2021	0.0%
Shares held by quarter Peak holding20.7M (Q2'26) Change over 8 quarters+4.3M Share of the company12.220% BlackRock, Inc.'s full portfolio →
AV ARCH Venture Management, LLC	12.7M	7.50%	−222.5K (−1.7%)	2025	11.8%
Shares held by quarter Peak holding12.9M (Q2'25) Change over 8 quarters+12.7M Share of the company7.500% ARCH Venture Management, LLC's full portfolio →

BlackRock, Inc.

20.7M

% of company

12.22%

Change vs last qtr

+2.7M (+14.9%)

Held since

≤2021

ARCH Venture Management, LLC

12.7M

% of company

7.50%

Change vs last qtr

−222.5K (−1.7%)

Held since

2025

28 more super investors behind a free account

See every manager holding Vir Biotechnology, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting VIR on Form N-PORT; together they hold 32.2% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
IC iShares Core S&P Small-Cap ETF iShares Trust	$74.6M	7.3M	4.32%	0.07%	June 30, 2026
SS State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR Series Trust	$50.4M	4.9M	2.92%	0.47%	June 30, 2026

iShares Core S&P Small-Cap ETF

iShares Trust

Position value

$74.6M

% of company

4.32%

% of the fund

0.07%

As of

June 30, 2026

State Street(R) SPDR(R) S&P(R) Biotech ETF

SPDR Series Trust

Position value

$50.4M

% of company

2.92%

% of the fund

0.47%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Vir Biotechnology, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
RN Robert Nelsen 5%+ holder 13D · 8.5%	13.5M	8.00%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company8.000% Disclosed stake13D · 8.5% View the 13D/G filing →
KC Keith Crandell 5%+ holder 13D · 8.3%	13.2M	7.79%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company7.790% Disclosed stake13D · 8.3% View the 13D/G filing →

Robert Nelsen

5%+ holder13D · 8.5%

13.5M

% of company

8.00%

Change vs last qtr

—

Held since

—

Keith Crandell

5%+ holder13D · 8.3%

13.2M

% of company

7.79%

Change vs last qtr

—

Held since

—

21 more holders behind a free account

See every insider and 5%+ holder of Vir Biotechnology, Inc..

Comments